Back to News
Earnings AnalysisMIR

MIR Q1 2026: Revenue +27.5% Confirms Cadence; FY26 Guide Reaffirmed Except CEO Grant

Matt RuncheySHORELINE, WA — April 28, 2026 · 4:30 PM PST7 min

Mirion Technologies reported Q1 2026 revenue of $257.6M, up 27.5% year over year on heavy Paragon, Certrec, and FX contribution, with Adjusted EBITDA of $54.3M (+16.3%) at a 21.1% margin and orders excluding the recent acquisitions of +19% to $241M. Management reaffirmed FY2026 organic growth (5-7%), Adjusted EBITDA ($285-300M), Adjusted EBITDA margin (25-26%), and Adjusted Free Cash Flow ($155-175M); only Adjusted EPS was revised down to $0.48-$0.55 (from $0.50-$0.57) to absorb a special one-time CEO retention grant disclosed Apr 13. The print is a clean confirmation of the cadence management telegraphed on the Q4 call: Q1 is the lightest quarter, margins compressed as Paragon dilution and a tough sensing comp absorbed roughly 200 bps, and the rest of the year requires a real ramp. Stock $18.68, down ~7% from the $20.14 prior thesis date. The committee holds price-at-value with MEDIUM confidence.

The Numbers

$257.6M
Q1 Revenue
+27.5% YoY (M&A + FX)
$54.3M
Adj. EBITDA
+16.3% YoY; 21.1% margin
+19%
Orders ex-Acquisitions
$241M; reported +42% to $288M
$0.48-$0.55
FY26 Adj. EPS
-$0.02 vs prior; CEO grant absorbed
The headline overstates what changed under the hood
Top-line +27.5% reads like an acceleration print, but the bulk is inorganic — Paragon's first full quarter, Certrec, and FX. The press release does not break out segment-level Q1 organic growth, which is the single most important data point for whether the FY2026 organic guide of 5-7% is on track. The Apr 29 conference call and the 10-Q will provide that data and will determine whether the Q1 organic-growth market resolves YES or NO before its May 15 deadline. The Narrative-Reality Gap signal stays DIVERGENT until that data lands.

Guidance: Reaffirmed Across Five of Six Lines

The press release explicitly reaffirmed FY2026 guidance on every operating metric and revised only the Adjusted EPS line for a governance item:

  • Total revenue growth: 22.0%-24.0% (REAFFIRMED — includes FX and acquisition tailwinds)
  • Organic growth: 5.0%-7.0% (REAFFIRMED — same range as the Q4 call)
  • Adjusted EBITDA: $285M-$300M (REAFFIRMED)
  • Adjusted EBITDA margin: 25.0%-26.0% (REAFFIRMED — well below the 30% margin probe in the ensemble)
  • Adjusted Free Cash Flow: $155M-$175M (REAFFIRMED; 54-58% conversion)
  • Adjusted EPS: $0.48-$0.55 (REVISED DOWN ~$0.02 from $0.50-$0.57 to absorb the Apr 13 special one-time CEO retention grant of performance-vesting stock options — governance, not operating)

Reaffirming five of six lines after one quarter is a credibility signal. The single revision is fully explained by an Apr 13 8-K disclosing a special grant to founder/CEO Tom Logan; the performance-vesting structure mitigates the alignment concern but the timing — a non-standard grant on top of regular compensation, mid-cycle — adds weight to the GOVERNANCE_ALIGNMENT MIXED watch list rather than changing the assessment outright.

Forecast Markets: Zero Resolved on the 8-K Alone

None of the seven active MIR markets resolves on the press release. The 8-K does not publish segment-level organic growth, large-pipeline conversion, RTQA-specific commentary, or H1/H2 margin phasing — those arrive on the Apr 29 call and in the 10-Q. The probability state heading into the call:

MarketProbabilityQ1 Read-Through
Q1 organic growth at/above guide (May 15)0.62Pending Apr 29 segment data; press release commentary on nuclear orders momentum is supportive
FY2026 organic growth above 5%0.48Reaffirmation of 5-7% range is supportive but not a resolution event
FY2026 Adj. EBITDA margin above 30%0.52Q1 21.1% + reaffirmed 25-26% guide leaves no realistic path; directionally negative for next refresh
Large pipeline conversion above $200M0.40Q1 ex-acquisition orders +19% supportive at the aggregate level; not project-level granular yet
Paragon margin dilution narrows by H20.55Q1 200 bps margin compression consistent with management framing of Q1 as the heaviest dilution quarter
RTQA returns to positive organic0.50Segment data not in 8-K; awaiting Apr 29 call
Insider selling decelerates through H10.45Resolves on Form 4 filings through Jul 15; Apr 13 CEO retention grant is governance-relevant but not a selling event

The clearest directional shift is the FY2026 30%+ margin market: Q1 21.1% combined with the reaffirmed 25-26% full-year guide leaves no realistic path to 30%, and the 0.52 ensemble probability is now skewed-high relative to fundamentals. The committee will let the next prediction refresh requantify rather than override the current ensemble on a single data point. The most immediate market — Q1 organic growth at or above guide, deadline May 15 — resolves once the segment data from the call or the 10-Q is in hand.

What Changed at the Signal Level

Seven lenses reviewed; six unchanged, one with mild watch-list additions. No signal-level reclassifications:

  • Insider Investigator — GOVERNANCE_ALIGNMENT: MIXED, with the Apr 13 special CEO retention grant added to the monitoring list. The performance-vesting structure mitigates the magnitude, but the grant warrants attention at the next proxy.
  • Gravy Gauge — REVENUE_DURABILITY: CONDITIONAL, lean positive. Order book +19% ex-acquisitions reinforces the nuclear-power durability case; segment Q1 organic still required to validate the 5-7% FY guide.
  • Myth Meter — NARRATIVE_REALITY_GAP: DIVERGENT. Headline +27.5% top-line overstates underlying organic momentum until segment disclosure closes the gap.
  • Stress Scanner — FUNDING_FRAGILITY: STRETCHED but stable. Cash $397.9M with $14.4M QoQ drawdown reflecting $16M treasury repurchase plus seasonal working capital; no debt actions, no covenant pressure.
  • Fugazi Filter — ACCOUNTING_INTEGRITY: QUESTIONABLE. SBC inclusion in Adjusted EPS now consistent across periods; no new accounting concerns surfaced in the 8-K.
  • Moat Mapper / Consolidation Calibrator: UNCHANGED. No moat-relevant disclosures and no new M&A; Paragon completing its first full quarter is on plan.
The bigger picture: confirmation, not resolution
Q1 confirms cadence but resolves nothing. The thesis questions that matter — does organic growth accelerate to 5-7%, does Paragon margin dilution narrow into H2, does the $400M+ large opportunity pipeline actually convert — all live downstream of this 8-K. The next material catalysts are the Apr 29 conference call (segment organic, Paragon margin commentary, large-pipeline progress), the 10-Q (full segment data), Form 4 cadence through H1, and the next proxy (CEO retention grant structure). The committee maintains price-at-value with MEDIUM confidence: the ~7% drift from $20.14 to $18.68 appears to reflect modest discomfort with the governance footnote plus generic April market chop, not a thesis-altering signal.

See the full six-lens MIR analysis

The March 2026 MIR deep-dive across Fugazi Filter, Gravy Gauge, Consolidation Calibrator, Moat Mapper, Stress Scanner, and Myth Meter, plus the seven forecast markets tracking the nuclear renaissance thesis.

Public Sources Used
  • MIR Q1 2026 Form 8-K (Item 2.02, Exhibit 99.1 press release; SEC EDGAR, filed 2026-04-28): SEC EDGAR
  • MIR Form 8-K Item 5.02 (special one-time CEO retention grant; filed 2026-04-13)
  • MIR FY2025 10-K (baseline analysis reference)
  • MIR Q4 2025 earnings call transcript (Feb 11, 2026; baseline reference)
  • MIR Q3 2025 / Q2 2025 / Q1 2025 earnings call transcripts

This report was generated by the Runchey Research AI Ensemble using primary SEC data and reviewed by Matthew Runchey for accuracy.

This analysis is for educational purposes only and does not constitute investment advice. See our Editorial Integrity & Disclosure Policy and Terms of Service.